North Wales, PA, United States of America

Chaozhong Cai

This inventor holds 17 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 11 EPO patents. Top assignee: Janssen Pharmaceutica Nv. Active years: 2009-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chaozhong Cai. Retrieved from https://idiyas.com/inventor/chaozhong-cai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 3)

% Patents Active = 70.6

CIPO Patents = 3

EPO Patents = 11 (Patent Applications = 10)

Average Co-Inventor Count = 3.9

ph-index = 8

Forward Citations = 152(Granted Patents)

Location History:

N. Wales, PA (US) (2010)
North Wales, PA (US) (2009 - 2020)

Company Filing History:

17 out of 2,101

Janssen Pharmaceutica Nv

patents

Years Active: 2009-2020

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10618893 - GPR120 agonists for the treatment of type II diabetes (2020-04-14),

2. 10213415 - Compounds as opioid receptor modulators (2019-02-26),

3. 10118922 - GPR120 agonists for the treatment of type II diabetes (2018-11-06),

4. 9700542 - Compounds as opioid receptor modulators (2017-07-11),

5. 9205076 - Compounds as opioid receptor modulators (2015-12-08),

6. 9024017 - Octahydro-cyclopentapyrrolyl antagonists of CCR2 (2015-05-05),

7. 8846655 - 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators (2014-09-30),

8. 8772325 - Compounds as opioid receptor modulators (2014-07-08),

9. 8685990 - Pyrimidine compounds as delta opioid receptor modulators (2014-04-01),

10. 8609709 - Compounds as opioid receptor modulators (2013-12-17),

11. 8513271 - Pyrimidine compounds as delta opioid receptor modulators (2013-08-20),

12. 8344011 - Compounds as opioid receptor modulators (2013-01-01),

13. 8269015 - 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2 (2012-09-18),

14. 8188287 - Piperidyl acrylamide antagonists of CCR2 (2012-05-29),

15. 7786158 - Compounds as opioid receptor modulators (2010-08-31),

Title: Chaozhong Cai: Innovator in Pharmaceutical Research

Introduction

Chaozhong Cai is a prominent inventor based in North Wales, PA (US), known for his significant contributions to pharmaceutical research. With a total of 17 patents to his name, he has made remarkable strides in the field of drug development, particularly in the treatment of metabolic and pain-related disorders.

Latest Patents

Cai's latest patents include innovative compounds aimed at addressing type II diabetes. One of his notable inventions involves GPR120 agonists, which are designed to modulate the GPR120 receptor to treat disorders influenced by this receptor. The compounds are represented by specific formulas, where various components are defined to ensure their efficacy. Additionally, he has developed novel opioid receptor modulators, which are directed towards improving treatments for disorders that can be ameliorated through opioid receptor modulation. These inventions not only showcase his expertise but also highlight his commitment to advancing medical science.

Career Highlights

Throughout his career, Chaozhong Cai has been associated with Janssen Pharmaceutica NV, a leading company in the pharmaceutical industry. His work at Janssen has allowed him to collaborate with other talented professionals and contribute to groundbreaking research that has the potential to improve patient outcomes.

Collaborations

Cai has worked alongside esteemed colleagues such as Wei He and Henry Joseph Breslin. Their collaborative efforts have fostered an environment of innovation and creativity, leading to the development of impactful pharmaceutical solutions.

Conclusion

Chaozhong Cai's contributions to the field of pharmaceutical research are noteworthy, with a focus on developing treatments for significant health issues. His innovative patents and collaborations reflect his dedication to improving healthcare through scientific advancements.

Profile summary based on public USPTO records.